^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ERY974

    i
    Other names: ERY974, ERY-974, ERY 974
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=179, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
    10ms
    A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=179, Recruiting, Chugai Pharmaceutical | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
    over3years
    A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=158, Recruiting, Chugai Pharmaceutical
    Clinical • New P1 trial • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
    over3years
    [VIRTUAL] ERY974, an Anti-Glypican 3/CD3 Bispecific T Cell-Redirecting Antibody for Treatment of Solid Tumors (PEGS 2021)
    ERY974 exerts strong anti-tumor activity against a variety of tumor models including those with a non-inflamed phenotype. In this talk, I will discuss the detailed preclinical characterization of ERY974, including the cytokine release mechanism and potential combination therapies.
    IO biomarker
    |
    GPC3 (Glypican 3)
    |
    ERY974
    almost4years
    [VIRTUAL] Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors. (AACR 2021)
    The observed responses and CRS side effects are markers of ERY974 biologic activity. At doses below 0.81 μg/kg (regimen A), ERY974 was generally well tolerated with a manageable toxicity profile, including ERY-induced CRS which was manageable with steroid administration and anti-IL6R therapy. Further research is required to determine if combined prophylactic anti-IL6R and steroid therapy is a more effective strategy for managing CRS.
    Clinical • P1 data
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • GPC3 (Glypican 3) • IL10 (Interleukin 10)
    |
    CXCL8 elevation
    |
    ERY974